Lung neuroendocrine neoplasm
MONDO:0005454A low, intermediate, or high grade malignant neoplasm with neuroendocrine differentiation that arises from the lung. This category includes typical carcinoid tumor, atypical carcinoid tumor, small cell carcinoma, large cell neuroendocrine carcinoma, and combined carcinoma.
Also known as: lung NET, lung neuroendocrine neoplasm, lung neuroendocrine tumor, lung neuroendocrine tumor, well differentiated, low or intermediate grade, lung neuroendocrine tumour, neuroendocrine neoplasm of lung, neuroendocrine neoplasm of the lung, pulmonary neuroendocrine neoplasm
1933 clinical trials for this condition and its sub-types, 21 tagged with Lung neuroendocrine neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Lung neuroendocrine neoplasm
-
Small cell lung carcinoma 514 trials · 515 incl. sub-types
2 sub-types
-
1 sub-type
-
Lung carcinoid tumor 2 trials
-
Combined lung carcinoma 0 trials · 1 incl. sub-types
2 sub-types
Most studied deeper sub-types
-
New Vaccine-Chemo combo shows promise for Tough-to-Treat tumors
Disease control PausedThis study tests whether adding a vaccine called SurVaxM to the chemotherapy drug temozolomide can help control advanced neuroendocrine tumors that are growing. About 60 adults with these rare cancers will receive either the combination or chemo alone. The goal is to see if the v…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New drug shows promise in slowing advanced neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy shows promise for early lung cancer
Disease control OngoingThis study tests whether adding an immunotherapy drug (nivolumab) to precise, high-dose radiation therapy helps prevent lung cancer from coming back in people with early-stage non-small cell lung cancer. About 140 participants will receive either radiation alone or radiation plus…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New radioactive therapy targets hard-to-treat thyroid cancer
Disease control OngoingThis early-phase study tests a radioactive drug (177Lu-PP-F11N) that seeks out and attaches to cancer cells in people with advanced medullary thyroid cancer and certain other neuroendocrine tumors. The goal is to see if the drug can help image tumors and deliver targeted radiatio…
Phase 1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental combo targets lung cancer brain metastases in early trial
Disease control OngoingThis early-phase trial is testing the safety and best dose of a drug called berzosertib when given together with whole brain radiation therapy. The study includes 15 people with lung cancer that has spread to the brain. The goal is to find out if this combination is safe enough t…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New pill shows promise for Hard-to-Treat neuroendocrine tumors
Disease control OngoingThis phase II trial is testing an oral drug called CVM-1118 in 34 people with advanced neuroendocrine tumors that have not responded to standard treatments. The drug aims to slow tumor growth and improve disease control. Participants take the pill twice daily, with a possible dos…
Phase 2 • Sponsor: TaiRx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
First human trial launches for targeted radiation therapy against Hard-to-Treat neuroendocrine tumors
Disease control OngoingThis early-phase study tests a new radioactive drug, [212Pb] VMT-α-NET, in 24 adults with advanced neuroendocrine tumors that have not responded to other treatments. The main goal is to find a safe dose for future studies, not to treat the disease. Participants receive up to two …
Early phase 1 • Sponsor: David Bushnell • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Which scan spots hidden tumors best? new study aims to find out
Diagnosis OngoingThis study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get …
Phase 2 • Sponsor: University of Alberta • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
Massive study aims to unravel best treatments for neuroendocrine tumors
Knowledge-focused OngoingThis study follows over 2,500 people with neuroendocrine tumors (NETs) to understand their symptoms and how treatments are chosen. Participants fill out surveys about quality of life and care experiences over 18 months. Researchers will link this to medical records to find which …
Sponsor: University of Iowa • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC